Harrison.ai Expands Open AI Platform, Challenging Market Norms

VIENNA – March 04, 2026 – Harrison.ai announced a significant expansion of its Open Platform today, welcoming four new artificial intelligence partners in a move designed to accelerate the adoption of medical imaging AI. The addition of AIRAmed, Koios Medical, Lunit, and Nanox AI diversifies the platform's offerings and reinforces its disruptive business model, which challenges the high costs and vendor lock-in common in the healthcare technology sector.

This expansion builds on the platform's launch last year, broadening its catalog of AI solutions for X-rays, CTs, MRIs, mammography, and ultrasound. For healthcare organizations, the move promises greater choice and transparency, granting them access to a growing ecosystem of specialized diagnostic tools without the typical marketplace fees that can stifle innovation and limit accessibility.

A New Paradigm for AI Adoption

At the core of Harrison.ai's strategy is a business model that fundamentally rethinks how hospitals and clinics procure and deploy AI. The Open Platform operates on what the company calls a "zero mark-up" and "radically open architecture" model. Unlike traditional AI marketplaces, which can charge platform fees ranging from 30% to 60% of an algorithm's cost, Harrison.ai does not add a surcharge. Healthcare providers pay the algorithm developer directly, enabling a more transparent and cost-effective transaction.

This approach aims to solve a major pain point for healthcare providers: integration fatigue and cost. The platform is built to provide a single, unified integration point with a hospital's existing Picture Archiving and Communication System (PACS), Radiology Information System (RIS), and Electronic Health Record (EHR). This eliminates the need for separate, costly, and time-consuming integrations for each new AI tool. Once connected, providers can access a full catalog of applications from various vendors.

Furthering its commitment to openness, the company has pledged not to block competing applications, even those that rival its own native solutions. This philosophy directly counters the vendor lock-in that often forces healthcare systems into restrictive, long-term contracts, instead fostering an environment where the best tools can be selected based on clinical merit and return on investment.

Expanding the Clinical AI Toolkit

The four new partners bring a wealth of specialized expertise, significantly enhancing the clinical depth and breadth of the platform. Each company addresses critical needs across different imaging domains, providing clinicians with more powerful tools to improve diagnostic accuracy and efficiency.

• AIRAmed specializes in neurology, offering AI that performs quantitative MR volumetry of the brain. This is particularly critical with the emergence of new Alzheimer's therapies. "Early detection and reliable differential diagnosis are critical, as subtle neurodegenerative changes are often not visible through visual assessment alone," said Dr. Tobias Lindig, CEO of AIRAmed. "Through our partnership with Harrison.ai, we are expanding access to objective, reproducible brain imaging biomarkers that integrate seamlessly into clinical workflows."

• Koios Medical focuses on decision support for breast and thyroid cancer diagnosis using ultrasound. Their technology is designed to improve accuracy and reduce unnecessary biopsies. "On behalf of Team Koios, we could not be happier to be working closely and aligned with our friends and colleagues at Harrison AI," stated Chad McClennan, President & CEO of Koios Medical. "There is no doubt we are like-minded in terms of our commitment to patient care, provider access to proven solutions and delivering excellent patient and customer experiences."

• Lunit, a globally recognized name in oncology AI, brings a suite of solutions for cancer screening and treatment. "We are delighted to establish this partnership with Harrison.ai, which reflects our shared ambition to advance the adoption of AI in healthcare," said Brandon Suh, Chief Executive Officer of Lunit. "The Harrison Open Platform offers an exceptional foundation for Lunit's solutions to be surfaced to customers in key markets."

• Nanox AI contributes solutions that support preventive imaging, leveraging its expertise to help healthcare systems implement proactive care strategies. "Through our collaboration with Harrison.ai, we are expanding Nanox’s commercial footprint by bringing AI solutions with demonstrated real‑world value to healthcare providers at scale," commented Erez Meltzer, Chief Executive Officer of Nanox.

Reshaping the Competitive Landscape

Harrison.ai's strategy positions it as a significant disruptor in a competitive field that includes established AI vendors and other platform providers like Aidoc, deepcOS, and Blackford. By distinguishing its offering as a "true clinical AI platform" rather than a simple marketplace or reseller, the company is betting that infrastructure and interoperability are as important as the algorithms themselves.

A true platform provides not just a catalog of tools but also the underlying operating system for intelligent orchestration of multiple algorithms and unified workflows. This is a crucial distinction for healthcare systems burdened by fragmented technologies. The single-integration, zero-markup model directly addresses the primary barriers to AI adoption—cost and complexity—potentially forcing competitors to re-evaluate their own pricing structures and value propositions.

The model may also foster a healthier market for AI developers. By removing the financial gatekeeper, the platform allows developers of highly specialized or niche algorithms to reach customers more economically. This could shift the competitive focus away from platform fees and toward the clinical efficacy and ROI of the AI tools themselves, empowering providers to choose solutions based purely on what works best for their patients and workflows.

A Foundation for Global Scale and Future Growth

This expansion is not just about adding partners; it is about leveraging a scalable foundation for global growth. Harrison.ai already has a significant international presence, with its solutions deployed at over 1,000 sites in more than 40 countries, including extensive use within the UK's NHS and across all public emergency departments in Hong Kong. This existing network provides a powerful distribution channel for its new and existing platform partners.

The platform's open architecture is designed to evolve alongside the rapidly advancing field of medical AI. As new technologies and clinical requirements emerge, the system is built to incorporate them without requiring massive overhauls from the end-user. By fostering collaboration across the entire ecosystem—from AI developers to healthcare providers—Harrison.ai is positioning its Open Platform not just as a product, but as a central hub designed to support the future of data-driven medicine on a global scale.